Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823035 | 0.78 | HTR2A (0.41) | HTR2AELANEGRM5CYP1B1ALDH1A1 | |
| SCHEMBL135178 | 0.76 | LIPG (0.36) | ALDH1A1HPGDDAOGABRA1GABRB2 | |
| SCHEMBL23043189 | 0.76 | HTR2A (0.40) | HTR2AELANEGRM5CYP1B1ALDH1A1 | |
| SCHEMBL31733100 | 0.76 | HTR2A (0.44) | HTR2AELANEGRM5CYP1A2DAO | |
| SCHEMBL31733104 | 0.76 | HTR2A (0.40) | HTR2AELANEGRM5CYP1B1ALDH1A1 | |
| SCHEMBL18378609 | 0.76 | ELANE (0.44) | HTR2AELANEGRM5CYP1B1ALDH1A1 | |
| SCHEMBL5033567 | 0.76 | HTR2A (0.37) | HTR2AELANEGRM5CYP1B1ALDH1A1 | |
| SCHEMBL818006 | 0.75 | KDM4E (0.35) | ELANEGRM5ALDH1A1HPGDTSHR | |
| SCHEMBL16950488 | 0.75 | GRM5 (0.36) | ELANEGRM5TSHRDAOGABRA1 | |
| SCHEMBL16954490 | 0.73 | GABRA1 (0.46) | GRM5ALDH1A1HPGDDAOGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |